London School of Hygiene and Tropical Medicine, London
Search for other papers by Peter N. Taylor in
Google Scholar
PubMed
Search for other papers by Bijay Vaidya in
Google Scholar
PubMed
, and currently a key debate amongst endocrinologists. Anti-thyroid drugs (ATDs) have been used since the 1940s, and are the preferred treatment during pregnancy. Radio-iodine is absolutely contraindicated [ 2 , 3 ], and thyroidectomy in pregnancy
Search for other papers by Suresh Kumar Bunker in
Google Scholar
PubMed
Search for other papers by Jagneshwar Dandapat in
Google Scholar
PubMed
Search for other papers by Gagan B.N. Chainy in
Google Scholar
PubMed
Search for other papers by Sunil Kumar Sahoo in
Google Scholar
PubMed
Search for other papers by Prabhat Kumar Nayak in
Google Scholar
PubMed
Introduction Clinical use of 6-n-propyl-2-thiouracil (PTU), an anti-thyroid drug, in general and particularly in children is a matter of concern [ 1 , 2 ]. It has been reported that the interruption of actions of thyroid hormones by anti-thyroid
Department of Clinical Institute, Aalborg University, Aalborg, Denmark
Search for other papers by J Karmisholt in
Google Scholar
PubMed
Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark
Search for other papers by S L Andersen in
Google Scholar
PubMed
Department of Clinical Institute, Aalborg University, Aalborg, Denmark
Search for other papers by I Bulow-Pedersen in
Google Scholar
PubMed
Search for other papers by A Krejbjerg in
Google Scholar
PubMed
Search for other papers by B Nygaard in
Google Scholar
PubMed
Department of Clinical Institute, Aalborg University, Aalborg, Denmark
Search for other papers by A Carlé in
Google Scholar
PubMed
Introduction Graves’ hyperthyroidism (GH) is an autoimmune disease mainly affecting the thyroid gland ( 1 , 2 ). The disease is usually transient with remission occurring within a period of 1–2 years after treatment with anti-thyroid drugs
Search for other papers by Earn H. Gan in
Google Scholar
PubMed
Search for other papers by Anna L. Mitchell in
Google Scholar
PubMed
Search for other papers by Ruth Plummer in
Google Scholar
PubMed
Search for other papers by Simon Pearce in
Google Scholar
PubMed
Search for other papers by Petros Perros in
Google Scholar
PubMed
the first 12 weeks following anti-CTLA-4 therapy. In this case, Graves disease developed after 8 years of tremelimumab therapy for metastatic melanoma. Antithyroid drug therapy was safe and effective alongside anti-CTLA-4 therapy without
FMTS, Faculté de Médecine, Université de Strasbourg, Strasbourg
Search for other papers by Bernard Goichot in
Google Scholar
PubMed
Search for other papers by Stéphane Bouée in
Google Scholar
PubMed
Search for other papers by Claire Castello-Bridoux in
Google Scholar
PubMed
Inserm U1037, Université Paul Sabatier, Toulouse, France
Search for other papers by Philippe Caron in
Google Scholar
PubMed
, few studies have compared the results of the 3 available treatment options: medical treatment with synthetic antithyroid drugs (ATDs), treatment with iodine 131 ( 131 I), or surgery. Medical treatment blocks hormone synthesis and the release of thyroid
Search for other papers by Susanne Neumann in
Google Scholar
PubMed
Search for other papers by Christine C. Krieger in
Google Scholar
PubMed
Search for other papers by Marvin C. Gershengorn in
Google Scholar
PubMed
is, by inhibiting TSHR/IGF-1R crosstalk. Of note, teprotumumab has been shown to be effective in the treatment of patients with TED [ 14 - 16 ] and has recently been approved by the United State Food and Drug Administration (FDA) (TEPEZZA, https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-thyroid
Search for other papers by Murat Faik Erdoğan in
Google Scholar
PubMed
Search for other papers by Özgür Demir in
Google Scholar
PubMed
Search for other papers by Reyhan Ünlü Ersoy in
Google Scholar
PubMed
Search for other papers by Kamile Gül in
Google Scholar
PubMed
Search for other papers by Berna İmge Aydoğan in
Google Scholar
PubMed
Search for other papers by Ziynet Alphan Üç in
Google Scholar
PubMed
Search for other papers by Türkan Mete in
Google Scholar
PubMed
Search for other papers by Sibel Ertek in
Google Scholar
PubMed
Search for other papers by Uğur Ünlütürk in
Google Scholar
PubMed
Search for other papers by Bekir Çakır in
Google Scholar
PubMed
Search for other papers by Yalçın Aral in
Google Scholar
PubMed
Search for other papers by Serdar Güler in
Google Scholar
PubMed
Search for other papers by Sevim Güllü in
Google Scholar
PubMed
Search for other papers by Demet Çorapçıoğlu in
Google Scholar
PubMed
Search for other papers by Selçuk Dağdelen in
Google Scholar
PubMed
Search for other papers by Gürbüz Erdoğan in
Google Scholar
PubMed
' ophthalmopathy by achieving euthyroidism . Acta Endocrinol 1989;121(suppl 2):185-189. 14 Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O: TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs
Search for other papers by Martina Tavarelli in
Google Scholar
PubMed
Search for other papers by Julie Sarfati in
Google Scholar
PubMed
Search for other papers by Christian De Gennes in
Google Scholar
PubMed
Search for other papers by Julien Haroche in
Google Scholar
PubMed
Search for other papers by Camille Buffet in
Google Scholar
PubMed
Search for other papers by Cécile Ghander in
Google Scholar
PubMed
Search for other papers by Jean Marc Simon in
Google Scholar
PubMed
Search for other papers by Fabrice Ménégaux in
Google Scholar
PubMed
Search for other papers by Laurence Leenhardt in
Google Scholar
PubMed
electrophoresis were also present. Vascular endothelial growth factor (VEGF) dosage was normal. A diagnosis of HOA secondary to a paraneoplastic syndrome was made. The patient started therapy with colchicine, nonsteroidal anti-inflammatory drugs and opioids with
Search for other papers by Eddy Rijntjes in
Google Scholar
PubMed
Search for other papers by Philip Moritz Scholz in
Google Scholar
PubMed
Search for other papers by Govindasamy Mugesh in
Google Scholar
PubMed
Search for other papers by Josef Köhrle in
Google Scholar
PubMed
Introduction The thioamide compounds 6- n -propyl-2-thiouracil (PTU), methimazole (MMI) and carbimazole represent widely used anti-thyroid therapeutic drugs in the treatment of hyperthyroidism [ 1 ]. Their main pharmacological target is the
Search for other papers by Stefan Matei Constantinescu in
Google Scholar
PubMed
Search for other papers by Julien Hospel in
Google Scholar
PubMed
Search for other papers by Chantal Daumerie in
Google Scholar
PubMed
Search for other papers by Orsalia Alexopoulou in
Google Scholar
PubMed
Search for other papers by Dominique Maiter in
Google Scholar
PubMed
Search for other papers by Maria-Cristina Burlacu in
Google Scholar
PubMed
. Anti-thyroid drugs (ATD) have become the first-choice treatment for newly diagnosed Graves’ hyperthyroidism; however, this approach is hampered by a 50–55% relapse rate after an appropriate course of ATD ( 6 ). The presence of TED (thyroid eye disease